Skip to main content
S&P 5007,637.76+1.14%DOW51,778.04+0.61%NASDAQ26,418.30+1.69%BTC$76,480.00+0.54%ETH$2,449.85+1.75%GOLD$4,380.80-0.15%OIL$101.27-1.13%
Smart Investors Daily
CV

NASDAQ · CVKD

Cadrenal Therapeutics, Inc. Common Stock

Healthcare · Biotechnology

$1.08

Up+$0.04 (+3.70%)

Updated Sep 17, 2026, 8:55 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
22.83M
P/E ratio
-1.56
Dividend yield
0.00%
52-week range
$1.00 – $8.35
Volume
56.33K
Avg. volume
27.14K

Price performance

CVKD price history

1M range · 0 trading sessions · Daily adjusted prices

CVKD does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest CVKD news

The latest Smart Investors Daily articles mentioning CVKD.

Stock researchCompany · Overview

CVKD research

Overview

Company profile and research snapshot.

Company profile

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$32.00
Implied upside
—
Analysts
8
CVKD recent ratings
DateFirmRatingTarget
Apr 7, 2026HC Wainwright & Co.Buy—
May 16, 2025HC Wainwright & Co.Buy—
Nov 11, 2024HC Wainwright & Co.Buy—
Jun 6, 2024HC Wainwright & Co.Buy—
May 9, 2024HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

PONTE VEDRA, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, announced that CEO Quang X. Pham will participate in the 28th Annual H.C. Wainwright Global Investment Conference, September 14–16, 2026, at the Lotte New York Palace Hotel in New York City. A pre-recorded presentation from the Company will be available on demand

Yahoo · Aug 31, 2026

Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia

FDA Alignment on Primary Endpoint and Path Forward for Phase 3 Registration Study CAD-1005 Targets a Significant Unmet Need, with Approximately 50,000 Confirmed Acute HIT Diagnoses Annually in the U.S. and an Estimated $2 Billion in Peak Annual Revenue Opportunity PONTE VEDRA, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions,

Yahoo · Aug 31, 2026

CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise

By David Bautz, PhD NASDAQ: CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Launches Strategic Partnering Process for Cardiac Acute Critical Care Franchise Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) has launched a structured strategic partnering process for its Cardiac Acute Critical Care Franchise that is centered on three commercial pillars. At this time, the company will not be

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By